Furthermore, the IGF-1R signaling pathway is associated with resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) used for the treatment of NSCLC. Here, IGF1R is linked to non-small cell lung carcinoma.